Use of Benefit Corporations to Accelerate Access to Affordable Vaccines
Julie Bateman Low- and middle-income countries face the heaviest burden from vaccine-preventable diseases, yet many of these countries cannot afford critical vaccines. Vaccines are often protected by patents so that pharmaceutical companies can recoup development costs. Consequently, vaccine manufacturers in developing countries must wait until the patents expire to produce lower-cost generic vaccines. Additionally, when the development of new vaccines relies on existing patents, such development is hindered. Benefit corporations offer an opportunity for the private and public sectors to align interests in accelerating critical vaccine development. Vaccine developers, restructured as benefit corporations, could commit to both special licensing agreements...
Remembering the Public’s Interest in the Patent System – A Post-Grant Opposition Designed to Benefit the Public
Eric Williams The problems associated with the existence of bad patents and the need for an effective, inexpensive vehicle for challenging them are nothing new. Over the past twenty-five years, several laws were proposed and passed intending to remedy these ills. Most recently, Congress introduced a bill aimed at curbing the adverse effects of bad patents, and prominent policy organizations and commentators advocated for, inter alia, the adoption of a new post-grant opposition as an antidote to the poison of bad patents. While these recent developments are certainly promising, without due attention given to the “advancement or social benefit gained...